Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
Zhou's Room to Act Statement `Very Important,' Do Says
29:57 - Khiem Do, who helps oversee about $60 billion as Hong Kong-based head of Asian multi-asset strategy at Baring Asset Management Ltd., talks about China's economy, stock market, and central bank policy. He speaks with Angie Lau on Bloomberg Television's "Asia Edge." (Source: Bloomberg)
  • Europe Isn’t In a Strong Position to Let Greece Go: Do
  • Chinese Airline Stocks Soar on Low Fuel Prices
  • Five Ways the Grexit Could Happen